文献速递血栓与止血

如何治疗抗凝难治性血栓性抗磷脂综合征

How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome.
PubMed 文献 · Blood · 2021-01-01

血栓性抗磷脂综合征(APS)的标准治疗是终身使用维生素K拮抗剂(VKA)口服抗凝,一般为华法林。少数APS患者尽管抗凝看似充分仍反复血栓形成,被视为抗凝难治。抗凝难治性APS的处理在很大程度上是经验性的,需从其他临床类似情况外推。

要点

  • 血栓性APS标准治疗为终身VKA口服抗凝,一般用华法林。
  • 少数患者抗凝看似充分仍反复血栓形成,视为抗凝难治。
  • 抗凝难治性APS的处理 largely 经验性,需从类似临床情况外推。

核心结论

  • 抗凝难治性血栓性APS的处理 largely 是经验性的,并从其他临床类似情况外推。
  • 抗凝难治性血栓性APS患者可能合并APS相关血小板减少,需在复发血栓与出血风险间平衡以达到充分抗凝。
  • APS血栓表型涉及多种机制,提示单用抗凝可能无法控制血栓形成。
  • 需多中心研究指导抗凝难治性血栓性APS患者的干预顺序及比较疗效。

研究设计与样本

  • 原文为叙述性综述(How I treat 格式),未报告系统检索范围。

主要发现

  • APS标准治疗为终身VKA口服抗凝,一般用华法林。
  • 少数APS患者抗凝看似充分仍反复血栓形成,被视为抗凝难治。
  • 进一步选择包括提高VKA抗凝强度或替代抗血栓策略,如低分子肝素、磺达肝癸钠、加用抗血小板治疗及考虑血管选项。
  • 辅助治疗(羟氯喹、他汀类和维生素D)用于APS相关血栓、免疫调节治疗及补体抑制值得考虑。
  • APS患者可能合并系统性红斑狼疮,增加血栓栓塞性疾病管理的复杂性。

临床怎么用

  • 原文未据此给出推荐。
  • 原文结论指出,通过关注细节并审慎应用有限数据,有可能将抗凝难治性血栓性APS所致疾病负担降至最低。

局限性

  • 原文指出抗凝难治性APS的处理 largely 是经验性的,并从其他临床类似情况外推。
  • 原文指出需多中心研究指导干预顺序及比较疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard treatment of thrombotic antiphospholipid syndrome (APS) is lifelong oral anticoagulation with a vitamin K antagonist (VKA), generally warfarin. A minority of patients with APS rethrombose despite seemingly adequate anticoagulation. These patients are deemed anticoagulant refractory. The management of anticoagulant-refractory APS is largely empirical and extrapolated from other clinically similar situations. Further options include increased VKA anticoagulation intensity or alternative antithrombotic strategies, including low-molecular-weight heparin, fondaparinux, the addition of antiplatelet therapy, and consideration of vascular options. Patients with anticoagulant-refractory thrombotic APS may have APS-associated thrombocytopenia, which necessitates balancing the risk of recurrent thrombosis vs bleeding to achieve adequate anticoagulation. The multiple mechanisms involved in the generation of the thrombotic phenotype in APS suggest that anticoagulation alone may not control thrombosis. Thus, other modalities, including adjunctive treatment (hydroxychloroquine, statins, and vitamin D) for APS-related thrombosis, merit consideration, as do immunomodulatory therapy and complement inhibition. Patients with APS may have coexistent systemic lupus erythematosus, which adds to the complexity of managing their thromboembolic disease. However, with attention to detail and judicious application of the limited data, it is possible to minimize the morbidity resulting from anticoagulant-refractory thrombotic APS. Multicenter studies are required to guide the sequence of interventions and their comparative efficacy in patients with anticoagulant-refractory thrombotic APS.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cohen H, Isenberg DA. How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. Blood. 2021. PMID: 32898856. doi:10.1182/blood.2020004942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。